ISSN: 1300 - 6525 E-ISSN: 2149 - 0880
kulak burun boğaz
ve baş boyun cerrahisi dergisi
http://dergi.kbb-bbc.org.tr
Kayıtlı İndeksler





REVIEW ARTICLES

Systematic Review on Allergic Rhinitis the Diagnosis and the Effectiveness of Topical Antihistamine-Steroid Combinations in Treatment
Alerjik Rinit Tanısı ve Tedavide Topikal Antihistamin-Steroid Kombinasyonlarının Etkinliği Üzerine Sistematik Derleme
Received Date : 14 Mar 2021
Accepted Date : 24 May 2021
Available Online : 16 Jun 2021
Doi: 10.24179/kbbbbc.2021-83069 - Makale Dili: TR
KBB ve BBC Dergisi. 2021;29(4):276-85
Copyright © 2020 by Turkey Association of Society of Ear Nose Throat and Head Neck Surgery. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Allergic rhinitis (AR) is a common social health affecting approximately 500 million people worldwide, and AR is seen at a rate of 23% in adults in our country. The effect of this respiratory disease, which has a social burden, is not only seen in the nasal mucosa. It also plays a role in the emergence or aggravation of lower respiratory tract diseases such as asthma. Other diseases of the nasal mucosa have similar effects in cases of local allergic rhinitis (LAR) and non-allergic rhinitis (NAR). According to the recommendations of the World Health Organization, its primary protection is to prevent the occurrence of pathogenesis steps. Tertiary prevention, pharmacotherapy seems to be the only option available, as primary and secondary prevention are not successful. In addition to the existing ones, the new topical combination of steroid and antihistamine is an important option in AR, LAR and NAR cases where expectations are not met when other treatment options are used. According to the systematic literature review data, it has been shown that its long-term use is safe and effective. AR treatment needs to be individualized specific to the patient’s symptoms.
ÖZET
Alerjik rinit (AR) dünya genelinde yaklaşık 500 milyon kişiyi etkileyen yaygın bir toplumsal sağlık olup, ülkemizde de AR erişkinlerde %23 oranında görülmektedir. Toplumsal yükü olan bu solunum yolu hastalığının etkisi sadece nazal mukozada görülmemektedir. Aynı zamanda astım gibi alt solunum yolu hastalıklarının ortaya çıkmasında veya ağırlaşmasında rol oynamaktadır. Nazal mukozanın diğer hastalıkları lokal alerjik rinit (LAR) ve nonalerjik rinit (NAR) olgularının da benzer etkileri bulunmaktadır. Dünya Sağlık Örgütü önerilerine göre birincil korunması, patogenez basamaklarının gerçekleşmesinin önlenmesidir. Birincil ve ikincil koruma başarılı olmadığı için üçüncül koruma, farmakoterapi elimizdeki tek seçenek olarak görünmektedir. Mevcut kullanılanlara ek olarak yeni topikal steroid ve antihistamin kombinasyonu, diğer tedavi seçeneklerin kullanıldığında beklentilerin karşılanmadığı AR, LAR ve NAR olgularında önemli bir seçenektir. Gerçekleştirilen sistematik literatür derlemesi verilerine göre uzun dönemli kullanımı, güvenli ve etkin olduğu ortaya konulmuştur. AR tedavisinin hastanın yakınmalarına özgü bireyselleştirilmesi gerekmektedir.
KAYNAKLAR
  1. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al; World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8-160. [PubMed] 
  2. Zuberbier T, Lötvall J, Simoens S, Subramanian SV, Church MK. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy. 2014;69(10):1275-9. [Crossref] [PubMed] 
  3. Cingi C, Songu M, Ural A, Annesi-Maesano I, Erdogmus N, Bal C, et al. The Score For Allergic Rhinitis study in Turkey. Am J Rhinol Allergy 2011;25:333-7. [Crossref]  [PubMed] 
  4. Ecevit MC, Özcan M, Haberal Can İ, Çadallı Tatar E, Özer S, Esen E, et al. Turkish guidelines for diagnosis and treatment of allergic rhinitis. Turk Arch Otorhinolaryngol 2021;59 (Suppl 1 ) In Press. [Crossref]  [PubMed]  [PMC] 
  5. [Erişim tarihi: 16.03.2021]. Erişim linki: [Link] 
  6. Cingi C, Bayar Muluk N, Scadding GK. Will every child have allergic rhinitis soon? Int J Pediatr Otorhinolaryngol. 2019;118:53-8. [Crossref] [PubMed] 
  7. Bosnic-Anticevich S, Costa E, Menditto E, Lourenço O, Novellino E, Bialek S, et al. ARIA pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy": AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project. Allergy. 2019;74(7): 1219-36. [PubMed] 
  8. Civelek E, Yavuz ST, Boz AB, Orhan F, Yuksel H, Uner A, et al. Epidemiology and burden of rhinitis and rhinoconjunctivitis in 9- to 11-year-old children. Am J Rhinol Allergy. 2010; 24(5):364-70. [Crossref]  [PubMed] 
  9. Cingi C, Topuz B, Songu M, Kara CO, Ural A, Yaz A, et al. Prevalence of allergic rhinitis among the adult population in Turkey. Acta Otolaryngol. 2010;130(5):600-6. [Crossref] [PubMed] 
  10. Aktaş A, Rahman S, Elbi H, Özyurt BC. Üniversite öğrencilerinde allerjik rinit sıklığı ve iliskli faktörler. Frequency of Allergic Rhinitis and Associated Factors in University Students CBU-SBED. 2015;2(2):36-40.
  11. Çobanoğlu HB, Işık AÜ, Topbaş M, Ural A. Prevalence of allergic rhinitis in children in the Trabzon province of the black sea region of Turkey. Turk Arch Otorhinolaryngol. 2016; 54(1): 21-8. [Crossref] [PubMed] [PMC] 
  12. Yang HJ, Kim YH, Lee B, Kong DY, Kim DK, Kim MA, et al; Work Group for Rhinitis, the Korean Academy of Asthma, Allergy and Clinical Immunology. Unmet primary physicians' needs for allergic rhinitis care in Korea. Allergy Asthma Immunol Res. 2017;9(3):265-71. [Crossref] [PubMed] [PMC] 
  13. Price DB, Scadding G, Bachert C, Saleh H, Nasser S, Carter V, et al. UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study. NPJ Prim Care Respir Med. 2016;23;26: 16033. [Crossref] [PubMed] [PMC] 
  14. Prepageran N, Wang de Y, Nair G, Maurer M. The status quo and unmet needs in the management of allergic rhinitis and chronic rhinosinusitis: a Malaysian perspective. Asia Pac Allergy. 2014;4(3):142-8. [Crossref] [PubMed] [PMC] 
  15. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011;17;378 (9809):2112-22. [Crossref] [PubMed] 
  16. Becker M, Reuter S, Friedrich P, Doener F, Michel A, Bopp T, et al. Genetic variation determines mast cell functions in experimental asthma. J Immunol. 2011;15;186(12):7225-31. [Crossref] [PubMed] 
  17. Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. Altered epigenetic regulation and increasing severity of bronchial hyperresponsiveness in atopic asthmatic children. J Allergy Clin Immunol. 2009;124(5):1116-8. [Crossref] [PubMed] 
  18. Schäper C, Gustavus B, Koch B, Ewert R, Felix SB, Kunkel G, et al. Effect of fluticasone on neuropeptides in nasal lavage in persistent allergic rhinitis. J Investig Allergol Clin Immunol. 2010;20(3):214-21. [PubMed] 
  19. Hanf G, Schierhorn K, Brunnée T, Noga O, Verges D, Kunkel G. Substance P induced histamine release from nasal mucosa of subjects with and without allergic rhinitis. Inflamm Res. 2000;49(10):520-3. [Crossref] [PubMed] 
  20. Ishida A, Ohta N, Koike S, Aoyagi M, Yamakawa M. Overexpression of glucocorticoid receptor-beta in severe allergic rhinitis. Auris Nasus Larynx. 2010;37(5):584-8. [Crossref] [PubMed] 
  21. Takeda K, Takeno S, Hirakawa K, Ishino T. Expression and distribution of glucocorticoid receptor isoforms in eosinophilic chronic rhinosinusitis. Auris Nasus Larynx. 2010;37(6): 700-7. [Crossref] [PubMed] 
  22. Yum HY, Ha EK, Shin YH, Han MY. Prevalence, comorbidities, diagnosis, and treatment of non-allergic rhinitis: real-world comparison with allergic rhinitis. Clin Exp Pediatr. 2020:10. [PubMed] 
  23. Eguiluz-Gracia I, Pérez-Sánchez N, Bogas G, Campo P, Rondón C. How to diagnose and treat local allergic rhinitis: a challenge for clinicians. J Clin Med. 2019;19;8(7):1062. [Crossref] [PubMed] [PMC] 
  24. Beard S. Rhinitis. Prim Care. 2014;41(1):33-46. [Crossref] [PubMed] [PMC] 
  25. Rondón C, Campo P, Zambonino MA, Blanca-Lopez N, Torres MJ, Melendez L, et al. Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis. J Allergy Clin Immunol. 2014;133(4):1026-31. [Crossref] [PubMed] 
  26. Eguíluz-Gracia I, Bosco A, Dollner R, Melum GR, Lexberg MH, Jones AC, et al. Rapid recruitment of CD14(+) monocytes in experimentally induced allergic rhinitis in human subjects. J Allergy Clin Immunol. 2016;137(6): 1872-81.e12. [Crossref] [PubMed] 
  27. Hong J, Bielory B, Rosenberg JL, Bielory L. Efficacy of intranasal corticosteroids for the ocular symptoms of allergic rhinitis: a systematic review. Allergy Asthma Proc. 2011;32(1):22-35. [Crossref] [PubMed] 
  28. Villa E, Magnoni MS, Micheli D, Canonica GW. A review of the use of fluticasone furoate since its launch. Expert Opin Pharmacother. 2011; 12(13):2107-17. [Crossref] [PubMed] 
  29. Sardana N, Santos C, Lehman E, Craig T. A comparison of intranasal corticosteroid, leukotriene receptor antagonist, and topical antihistamine in reducing symptoms of perennial allergic rhinitis as assessed through the Rhinitis Severity Score. Allergy Asthma Proc. 2010;31(1):5-9. [Crossref] [PubMed] 
  30. Schröder K, Finis D, Meller S, Buhren BA, Wagenmann M, Geerling G. Die saisonale und perenniale allergische Rhinokonjunktivitis [Seasonal and perennial allergic rhinoconjunctivitis]. Klin Monbl Augenheilkd. 2014;231: 496-504. [Crossref]  [PubMed] 
  31. Melvin TA, Patel AA. Pharmacotherapy for allergic rhinitis. Otolaryngol Clin North Am. 2011;44(3):727-39. [Crossref] [PubMed] 
  32. Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc. 2011;32(6):413-8. [Crossref] [PubMed] 
  33. Berger W, Meltzer EO, Amar N, Fox AT, Just J, Muraro A, et al. Efficacy of MP-AzeFlu in children with seasonal allergic rhinitis: importance of paediatric symptom assessment. Pediatr Allergy Immunol. 2016;27(2):126-33. [Crossref] [PubMed] 
  34. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23(7):495-503. [PubMed] 
  35. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013; 161(4):369-77. [Crossref] [PubMed] 
  36. Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract. 2018;6(5):1726-32.e6. [Crossref] [PubMed] 
  37. Kortekaas Krohn I, Callebaut I, Alpizar YA, Steelant B, Van Gerven L, Skov PS, et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy. 2018;73(5):1084-93. [Crossref] [PubMed] 
  38. Carr WW, Ratner P, Munzel U, Murray R, Price D, Canonica GW, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc. 2012;33(6):450-8. [Crossref] [PubMed] 
  39. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydroch loride and fluticasone propionate in an advanced delivery system) in subjects with chro nic rhinitis. J Allergy Clin Immunol Pract. 2014; 2(2):179-85. [Crossref] [PubMed] 
  40. Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33(4):324-32. [Crossref] [PubMed] 
  41. Derendorf H, Munzel U, Petzold U, Maus J, Mascher H, Hermann R, Bousquet J. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a novel aqueous nasal spray. Br J Clin Pharmacol. 2012;74(1):125-33. [Crossref] [PubMed] [PMC] 
  42. Ilyina NI, Edin AS, Astafieva NG, Lopatin AS, Sidorenko IV, Ukhanova OP, et al. Efficacy of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, delivered in a single spray, for the treatment of seasonal allergic rhinitis: results from Russia. Int Arch Allergy Immunol. 2019;178(3):255-63. [Crossref] [PubMed] 
  43. Berger W, Sher E, Gawchik S, Fineman S. Safety of a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in children: a randomized clinical trial. Allergy Asthma Proc. 2018;1;39(2):110-6. [Crossref] [PubMed] [PMC] 
  44. Debbaneh PM, Bareiss AK, Wise SK, McCoul ED. Intranasal azelastine and fluticasone as combination therapy for allergic rhinitis: systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2019;161(3):412-8. [Crossref] [PubMed]